AstraZeneca PE Ratio 2006-2018 | AZN

Current and historical p/e ratio for AstraZeneca (AZN) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AstraZeneca PE ratio as of November 16, 2018 is 12.79.
AstraZeneca PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-11-16 40.67 25.90
2018-09-30 39.57 $1.57 25.20
2018-06-30 34.72 $2.11 16.45
2018-03-31 34.58 $2.22 15.58
2017-12-31 33.38 $2.37 14.08
2017-09-30 32.59 $2.79 11.68
2017-06-30 32.30 $3.05 10.59
2017-03-31 29.50 $2.67 11.05
2016-12-31 25.06 $2.76 9.08
2016-09-30 30.14 $1.95 15.46
2016-06-30 27.32 $1.76 15.53
2016-03-31 25.49 $2.31 11.03
2015-12-31 29.79 $2.02 14.75
2015-09-30 27.92 $1.26 22.25
2015-06-30 27.58 $0.75 37.02
2015-03-31 29.62 $0.51 58.08
2014-12-31 29.63 $0.49 60.47
2014-09-30 30.08 $0.41 74.26
2014-06-30 30.88 $0.80 38.60
2014-03-31 26.96 $0.82 33.08
2013-12-31 23.98 $1.02 23.51
2013-09-30 20.97 $1.84 11.40
2013-06-30 18.77 $1.95 9.62
2013-03-31 19.83 $2.26 8.79
2012-12-31 18.01 $2.49 7.23
2012-09-30 18.23 $2.46 7.41
2012-06-30 16.73 $3.14 5.34
2012-03-31 16.63 $3.26 5.10
2011-12-31 16.59 $3.66 4.54
2011-09-30 15.90 $3.65 4.36
2011-06-30 17.61 $2.90 6.07
2011-03-31 16.22 $2.87 5.66
2010-12-31 15.64 $2.79 5.61
2010-09-30 17.16 $2.75 6.24
2010-06-30 15.74 $2.95 5.34
2010-03-31 14.93 $2.81 5.31
2009-12-31 15.10 $2.60 5.82
2009-09-30 14.46 $2.49 5.81
2009-06-30 14.02 $2.36 5.95
2009-03-31 11.26 $2.32 4.85
2008-12-31 12.54 $2.10 5.98
2008-09-30 13.41 $2.10 6.40
2008-06-30 12.85 $1.96 6.57
2008-03-31 11.48 $1.88 6.12
2007-12-31 12.50 $1.87 6.69
2007-09-30 14.62 $1.91 7.67
2007-06-30 15.46 $1.96 7.91
2007-03-31 15.51 $1.99 7.81
2006-12-31 15.16 $1.93 7.87
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $103.013B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.677B 18.36
Pfizer (PFE) United States $259.009B 14.60
Merck (MRK) United States $205.072B 17.77
Novartis AG (NVS) Switzerland $203.357B 17.38
AbbVie (ABBV) United States $137.681B 12.22
Eli Lilly (LLY) United States $120.583B 21.20
Sanofi (SNY) France $113.115B 14.01
Novo Nordisk (NVO) Denmark $107.931B 17.53
GlaxoSmithKline (GSK) United Kingdom $100.041B 13.45
Bristol-Myers Squibb (BMY) United States $88.253B 14.53